ProfileGDS5678 / 1449080_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 95% 93% 93% 93% 91% 91% 93% 92% 93% 92% 93% 92% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.831593
GSM967853U87-EV human glioblastoma xenograft - Control 28.4272495
GSM967854U87-EV human glioblastoma xenograft - Control 37.8409293
GSM967855U87-EV human glioblastoma xenograft - Control 47.9579193
GSM967856U87-EV human glioblastoma xenograft - Control 57.8751193
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2688391
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.122191
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.7252593
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.5035692
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.9155293
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6776292
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0375993
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.7414392
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.0397294